Plexiform neurofibromas in neurofibromatosis type 1: current and emergent therapeutic strategies
Rare Disease and Orphan Drugs Journal · 02.03.2026 · 5 (1)
DOI: 10.20517/rdodj.2025.52 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rare Disease and Orphan Drugs Journal, online erschienen am 02.03.2026. Verfasst von Hannah Kim und 2 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Neurofibromatosis type 1-associated plexiform neurofibromas cause significant morbidity and carry a risk of malignant transformation. Early targeted agents failed to demonstrate efficacy, safety, or durable responses until the discovery of mitogen-activated protein kinase kinase (MEK 1/2) inhibitors. Selumetinib and mirdametinib are approved medical therapies that can potentially reduce tumor volume and symptoms, improve patient-reported outcomes, and have manageable toxicities. An indirect comparison between selumetinib and mirdametinib suggests differences in efficacy and safety, but direct confirmatory head-to-head trials are needed. Active clinical trials in the pipeline are exploring other targets in the MEK pathway, along with combination therapies. Key priorities include the impact of malignant peripheral nerve sheath tumor risk, defining long-term safety, durability off therapy, predictors of response and resistance, and implementation of multidisciplinary care.
Zitieren
APA
Kim, H., Polen, J., & Kaur, G. (2026). Plexiform neurofibromas in neurofibromatosis type 1: current and emergent therapeutic strategies. Rare Disease and Orphan Drugs Journal, 5(1). https://doi.org/10.20517/rdodj.2025.52
Vancouver
Kim H, Polen J, Kaur G. Plexiform neurofibromas in neurofibromatosis type 1: current and emergent therapeutic strategies. Rare Disease and Orphan Drugs Journal. 2026;5(1). doi:10.20517/rdodj.2025.52
BibTeX
@article{Kim2026,
author = {Kim, Hannah and Polen, Julia and Kaur, Gurcharanjeet},
title = {Plexiform neurofibromas in neurofibromatosis type 1: current and emergent therapeutic strategies},
journal = {Rare Disease and Orphan Drugs Journal},
year = {2026},
volume = {5},
number = {1},
doi = {10.20517/rdodj.2025.52}
}
EUVIMED